Search Results
Your search for ,twO matches 11978 pages
Showing 1351 - 1400Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Julie E. Bauman, MD, MPH, and colleagues found that the combination of the antihepatocyte growth factor antibody ficlatuzumab and cetuximab was active in patients with cetuximab-resistant, recurrent or metastatic head and neck...
ChatGPT May Have Potential to Help Educate Patients With Cirrhosis and Hepatic Cancer in Basic Knowledge, Lifestyle, and Treatment Domains
Investigators revealed that the artificial intelligence (AI) chatbot ChatGPT may help improve health outcomes for patients with cirrhosis and hepatic cancer by providing easy-to-understand information about basic knowledge, lifestyle modifications, and treatment options for these conditions,...
Expert Point of View: Mikkael Sekeres, MD, MS
Commenting on these studies of menin inhibitors, Mikkael Sekeres, MD, MS, Professor of Medicine and Chief of the Division of Hematology at the Sylvester Cancer Center, University of Miami Miller School of Medicine, was enthusiastic about the promise of these agents because they are targeted to...
Menin Inhibitors Under Study in KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia
Menin inhibitors are making inroads in the treatment of acute myeloid leukemia (AML). These drugs selectively target KMT2A-rearranged or NPM1-mutant AML, and early studies suggest they will be a welcome addition for patients with these aberrations. KMT2A rearrangements occur in about 5% of patients ...
Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD Anderson
The inaugural MD Anderson Clinical Education Symposium on Immunotherapy Toxicity Management (IOTOX) welcomed more than 250 international attendees, both virtually and in person at The University of Texas MD Anderson Cancer Center in Houston on December 3, 2022. The symposium focused on bringing the ...
How Effectively Are You Helping Patients With Cancer at the End of Life?
“Providing hope when there is little to hope for is hard,” noted Hyman B. Muss, MD, Professor of Medicine and the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center. At the 2023 Miami...
ELCC 2023: New Data on Amivantamab-vmjw in Patients With Advanced NSCLC and EGFR Exon 20 Insertion Mutations
New long-term data from the CHRYSALIS study evaluating amivantamab-vmjw in patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy were presented by Lopez et al at the 2023 European Lung Cancer...
RUBY Trial in Endometrial Cancer and Breast Cancer Screening After Treatment
On this episode, we discuss two important studies presented over the past month at two oncology meetings, including the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer and the Miami Breast Cancer Conference.
Extended Performance of an Image-Based Short-Term Risk Model for Predicting Breast Cancer
In a Swedish case-cohort study reported in the Journal of Clinical Oncology, Eriksson et al found that an image-based short-term risk model outperformed a traditional lifestyle/familial risk–based risk model in predicting the likelihood of development of breast cancer over a 10-year period. Study...
Clinical Trial Participation May Be Associated With Improved Overall Survival in Patients With Ovarian Cancer
Investigators have found that patients with platinum-resistant epithelial ovarian cancer who participate in clinical trials may have higher rates of overall survival compared with those who don’t participate in clinical trials, according to findings presented by Morton et al at the Society of...
Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer
Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented by Ackroyd et al and Adjei et al at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on ...
Addition of Immunotherapy to Chemotherapy Regimen May Increase Progression-Free Survival in Patients With Advanced or Recurrent Endometrial Cancer
Adding immunotherapy to standard chemotherapy may result in significantly longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to the findings from two novel studies presented by Eskander et al and Mirza et al at the Society of Gynecologic Oncology...
Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods
In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....
Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo
Researchers have found no significant differences in overall survival between patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib or placebo, according to new findings presented by Matulonis et...
Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse events, and positive health outcomes in patients with ovarian cancer who have a germline...
Atezolizumab May Be an Effective Primer for Chemoradiation in Patients With Locally Advanced Cervical Cancer
After comparing the efficacy of the anti–PD-L1 inhibitor atezolizumab prior to and concurrently with chemoradiation, researchers have indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with...
Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer
In a phase IIb trial reported in JAMA Oncology, Serrano et al found that exemestane at 25 mg three times weekly was noninferior to the standard dosing of 25 mg once daily in terms of serum estradiol reduction among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast...
New Prognostic Staging System for De Novo Metastatic Breast Cancer
In a study reported in the Journal of Clinical Oncology, Jennifer K. Plichta, MD, MS, and colleagues formulated a novel prognostic staging system for de novo metastatic breast cancer. Study Details The staging system was developed using data from 42,467 patients from the National Cancer Database...
Naporafenib Plus Trametinib in Advanced NRAS-Mutant Melanoma
As reported in the Journal of Clinical Oncology by de Braud et al, findings in the expansion cohort of a phase Ib trial indicate activity with the combination of the BRAF/CRAF kinase inhibitor naporafenib and trametinib in patients with advanced or metastatic NRAS-mutant melanoma. Study Details In ...
Significance of the MGUS-Like Phenotype in Patients With Multiple Myeloma and Light Chain Amyloidosis
In a study reported in the Journal of Clinical Oncology, Burgos et al developed an algorithm to identify patients with multiple myeloma and light-chain amyloidosis who have the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype, as well as identified the association of the...
Lower-Income Patients With Early-Stage Esophageal Adenocarcinoma May Face Disparities in Cancer Care and Higher Mortality Rates
Patients with early-stage esophageal adenocarcinoma from lower-income households may be significantly less likely to receive a potentially life-saving treatment and may be more likely to die from the disease, according to a new study published by Geng et al in Clinical Gastroenterology and...
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
On March 24, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications. The accelerated approval pathway is...
Highlights From the SSO 2023 International Conference on Surgical Cancer Care
On this episode, we discuss two studies that were presented at the Society of Surgical Oncology (SSO) 2023 International Conference on Surgical Cancer Care. First, we’ll share results of the SWOG S1512 study of neoadjuvant pembrolizumab in patients with stage II to III desmoplastic melanoma. Then,...
ASCO Celebrates the Cancer Moonshot on Its Relaunch Anniversary
“Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of ...
ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...
Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation
As reported in The Lancet by Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
On January 27, 2023, pirtobrutinib was granted accelerated approval for treatment of relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.1 Pirtobrutinib is a noncovalent inhibitor of BTK. Supporting Efficacy...
10 Facts About Colorectal Cancer From the Colorectal Cancer Alliance
March is widely recognized worldwide as Colorectal Cancer Awareness month. Several advocacy groups and professional organizations recognize Colorectal Cancer Awareness month by promoting screening for eligible individuals and working to increase awareness. Here, the Colorectal Cancer Alliance, an...
Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber
Colorectal cancer is the third most common cancer among men and women of all ages in the United States and is on track to be the leading cause of cancer death in adults younger than 50 by 2030. The alarming rise of colorectal cancer in people younger than age 50 prompted the U.S. Preventive...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer
The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...
TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
Carl H. June, MD, FAACR, to Be Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research
The American Associationfor Cancer Research (AACR) will award Carl H. June, MD, FAACR, Fellow of the AACR Academy, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the 2023 AACR Annual Meeting, April 14–19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in ...
The Will to Go On
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of...
Early Exposure to Health-Care Inequities Sets the Stage for a Leadership Role in Global Oncology for Satish Gopal, MD, MPH
In this installment of The ASCO Post’s Global Oncology series, guest editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Satish Gopal, MD, MPH, Director of the Center for Global Health at the National Cancer Institute (NCI). In this role, he oversees the development of initiatives and...
Northwell Health Names Richard D. Carvajal, MD, to Lead Medical Oncology Programs
Northwell Health has appointed Richard D. Carvajal, MD, a clinician and researcher in melanoma and early-phase drug development, as Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute. He also was named the R. J. Zuckerberg Chair in Medical Oncology....
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Cancer Diagnostic Services Offered at a Community Health Center May Speed Diagnoses for Underserved Patients
In a new colocation model for cancer diagnostic services, researchers have found that a new program installed at a community health center that cares for historically underserved populations was able to reduce the time to cancer diagnosis from a median of 32 days to 12 days, according to an article ...
Laparoscopy-Assisted vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Relapse-Free Survival at 5 Years
As reported in JAMA Surgery by Etoh et al, 5-year follow-up of the Japanese phase II/III JLSSG0901 trial has shown noninferiority in relapse-free survival with laparoscopic-assisted distal gastrectomy vs open distal gastrectomy in patients with locally advanced gastric cancer. Study Details In the...
Pembrolizumab Plus Ifosfamide, Carboplatin, and Etoposide in Relapsed or Refractory Classical Hodgkin Lymphoma
In a phase II trial reported in JAMA Oncology, Locke J. Bryan, MD, and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory...
Does Discrimination Accelerate Aging in Black Cancer Survivors?
Investigators have found that Black cancer survivors who reported high levels of discrimination showed greater biological aging and frailty than those who reported lower levels of discrimination, according to a new study published by Mandelblatt et al in the journal Cancer. Background...
Study Reveals Potential Cause of Resistance to Revumenib in Patients With Acute Myeloid Leukemia
Use of the novel menin inhibitor revumenib has led to remissions in patients with acute myeloid leukemia (AML), and associated findings have suggested the mechanisms through which cancer cells may become resistant to such treatment, according to two studies published by Issa et al and Perner et al, ...
Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Renata Ferrarotto, MD, and colleagues found that the combination of axitinib and avelumab showed evidence of activity in patients with recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 28...
Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer
In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). New findings from the NEOSTAR study,...
Detection of Emphysema During Lung Cancer Screening
In an article published in Annals of the American Thoracic Society, James L. Mulshine, MD, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening presents an important opportunity to engage individuals with such ...
